Autoinjectors Market Analysis, Revenue Trends, Company Profiles, Revenue Share Till 2028

Comments · 147 Views

Autoinjectors Market Analysis, Revenue Trends, Company Profiles, Revenue Share Till 2028

Autoinjectors Market in terms of revenue was estimated to be worth $0.9 billion in 2023 and is poised to reach $1.7 billion by 2028, growing at a CAGR of 14.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. Whereas, the autoinjector finished formulations market is projected to reach USD 136.5 billion in 2028 from USD 59.6 billion in 2023, growing a CAGR of 18.0%. Some of the prominent factors driving the growth of this market are favorable government support and reimbursements and growing number of regulatory approvals for autoinjectors.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724

Prominent players in the market are

Becton, Dickinson and Company (BD) (US), Ypsomed Holding AG (Switzerland), SHL Medical (Switzerland), West Pharmaceutical Services, Inc. (US), Recipharm AB (Sweden), Haselmeier GmbH (Germany), Owen Mumford Ltd. (UK), Gerreshiemer AG (Germany), Philip-Medisize, LLC (US), Oval Medical Technologies Ltd. (UK), Solteam Incorporation Co., Ltd. (China), Elcam Drug Delivery Devices (E3D) (Israel), Antares Pharma, Inc. (US), Jabil, Inc. (US), and the some of the major market players for finished formulations covered in this chapter include AbbVie Inc. (US), Amgen Inc. (US), Eli Lilly and Company (US), Novartis AG (Switzerland), Merck KGaA (Germany), Viatris Inc. (US), and Biogen (US).

BD is the leading players in the global autoinjector devices market. The company offers self-injection device systems.

Ypsomed Holding AG is one of the leading players in the global autoinjector devices market. Ypsomed  offers self-injection device systems along with infusion systems.

Rheumatoid Arthritis subsegment accounted for the largest share of the autoinjectors market by therapy area

Among the therapy area, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapy areas. the rheumatoid arthritis segment accounted for the largest share of the autoinjectors market by therapy area.

Disposable usage is the fastest-growing segment of the autoinjectors market by usage

the disposable segment accounted for the fastest-growing share of the usage segment of autoinjectors market. Market growth can largely be attributed to the high convinience and ease of use for patients as the need for manual loading of drug in the injector is eliminated due to presence of prefilled syringe, and low chances of infections through used needle.

Inquire Before Buying @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=173991724

Europe: The second-largest region in the autoinjectors market.

The European autoinjectors market is the second-largest autoinjectors market globally, mainly due to factors such as presence of a large geriatric population in the region and the improving reimbursement and regulatory scenario. The presence of large geriatric population in the region is expected to increase the prevalence of chronic diseases leading consequently leading to growing adoption of autoinjectors for treatment of these disease.

This report categorizes the Autoinjectors Market market to forecast revenue and analyze trends in each of the following submarkets:

By Usage

  • Disposable Autoinjectors
  • Reusable Autoinjectors

By Technology

  • Manual Autoinjectors
  • Automatic Autoinjectors

By Route of Administration

  • Subcutaneous
  • Intramuscular

By Type

  • Rheumatoid arthritis
  • Diabetes
  • Multiple Sclerosis
  • Anaphylaxis
  • Other therapy areas

By Region

  • North America
  • Europe
  • Asia Pacific (APAC)
  • Latin America
  • Middle East and Africa

Buy this Research Report @ https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=173991724

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on TwitterLinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

Comments